FDA Issues Second Generic Lipitor Recall in Two Years, Bloomberg Reports

Published on March 10, 2014 by Sandy Liebhard

Text-Size:A A A+

 

An Indian drug maker’s recent shortfalls in Mumbai may have Lipitor lawsuit plaintiffs wondering about a future recall of its brand-name counterpart.

According to a Bloomberg.com report on March 10th, shares have fallen 3.9 percent for Ranbaxy Laborates Ltd. The company is pulling 64,626 bottles of atorvastatin calcium, also known as the generic version of Lipitor, from U.S. shelves after the U.S. Food and Drug Administration (FDA) received a complaint from a pharmacist who found a 20 milligram pill in a sealed bottle said to contain only 10 milligram tablets.

This is the second time in 15 months that a generic Lipitor recall has been issued. According to Bloomberg, the first announcement was made in November 2012 after the medication was shown to contain small glass particles. Ranbaxy has not disclosed whether the latest batches of the drug were made in its New Jersey plant, located in New Jersey, but has said they have no product complaints associated with the recalled batches. After failing to comply with FDA standards, four facilities in India are no longer permitted to send shipments to the U.S.

Cholesterol Drug Comes Under Fire in Lipitor Lawsuit Litigation

Meanwhile, lawsuits over the brand-name version of Lipitor have continued to gain momentum in the U.S. Court documents show at least 60 claims against Pfizer , many of which alleging Lipitor diabetes complications, now filed in the U.S. District Court for the District of South Carolina, where a multidistrict litigation (MDL) is now underway.

A court Order issued at the time this proceeding was created notes the filing of 170 additional claims that may be transferred to this location in the future by plaintiffs who allege new-onset Type 2 diabetes and other side effects stemming from the cholesterol-lowering medication. Individuals involved in Lipitor diabetes lawsuits say that Pfizer’s FDA-mandated labeling is inadequate in warning patients about its association with the disease.

In four claims now pending in the U.S. District Court, Northern District of West Virginia, four women allege that Pfizer had knowledge of Lipitor’s association with Type 2 diabetes and concealed it from the public. Court records show these lawsuits filed between February 3 and February 14th, 2014.

Filing a Lipitor Lawsuit

Contact our Firm to find out more about Lipitor lawsuits, and whether you may be eligible to file a claim seeking compensation for damages incurred by your alleged injuries. Call the following number for more information: .